Cargando…

Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH

Non-alcoholic steatosis (NAFLD) and steatohepatitis (NASH) are two highly prevalent human disorders for which therapy remains suboptimal. Bile acids are signaling molecules acting on two main receptors the Farnesoid-x-receptor (FXR) and G protein coupled receptor GPB AR1. Clinical trials have shown...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marchianò, Silvia, Biagioli, Michele, Morretta, Elva, Di Giorgio, Cristina, Roselli, Rosalinda, Bordoni, Martina, Bellini, Rachele, Urbani, Ginevra, Massa, Carmen, Monti, Maria Chiara, Zampella, Angela, Distrutti, Eleonora, Fiorucci, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884292/ https://www.ncbi.nlm.nih.gov/pubmed/36709356 http://dx.doi.org/10.1038/s41598-023-28647-4

Ejemplares similares

Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation
por: Carino, Adriana, et al.
Publicado: (2019)

GLP-1 Mediates Regulation of Colonic ACE2 Expression by the Bile Acid Receptor GPBAR1 in Inflammation
por: Biagioli, Michele, et al.
Publicado: (2022)

BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis
por: Carino, Adriana, et al.
Publicado: (2017)

Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma
por: Di Giorgio, Cristina, et al.
Publicado: (2023)

GPBAR1 Functions as Gatekeeper for Liver NKT Cells and provides Counterregulatory Signals in Mouse Models of Immune-Mediated Hepatitis
por: Biagioli, Michele, et al.
Publicado: (2019)

Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma
por: Di Giorgio, Cristina, et al.
Publicado: (2022)

Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands
por: Finamore, Claudia, et al.
Publicado: (2016)

Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis
por: Di Giorgio, Cristina, et al.
Publicado: (2022)

Discovery of a Potent and Orally Active Dual GPBAR1/CysLT(1)R Modulator for the Treatment of Metabolic Fatty Liver Disease
por: Fiorucci, Stefano, et al.
Publicado: (2022)

Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders
por: Fiorillo, Bianca, et al.
Publicado: (2023)

Correction to “Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders”
por: Fiorillo, Bianca, et al.
Publicado: (2023)

Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation
por: Biagioli, Michele, et al.
Publicado: (2020)

Gpbar1 agonism promotes a Pgc-1α-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice
por: Carino, Adriana, et al.
Publicado: (2017)

Expanding the Library of 1,2,4-Oxadiazole Derivatives: Discovery of New Farnesoid X Receptor (FXR) Antagonists/Pregnane X Receptor (PXR) Agonists
por: Finamore, Claudia, et al.
Publicado: (2023)

Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction
por: Biagioli, Michele, et al.
Publicado: (2021)

The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines
por: Carino, Adriana, et al.
Publicado: (2016)

VSL#3 Resets Insulin Signaling and Protects against NASH and Atherosclerosis in a Model of Genetic Dyslipidemia and Intestinal Inflammation
por: Mencarelli, Andrea, et al.
Publicado: (2012)

Bile Acids Activated Receptors Regulate Innate Immunity
por: Fiorucci, Stefano, et al.
Publicado: (2018)

Repurposing UDCA, an FXR Inhibitor, to Prevent SARS-Cov-2 Infection
por: Prayitno, Khairunnadiya, et al.
Publicado: (2023)

The Aryl Hydrocarbon Receptor (AhR) Mediates the Counter-Regulatory Effects of Pelargonidins in Models of Inflammation and Metabolic Dysfunctions
por: Biagioli, Michele, et al.
Publicado: (2019)

Analysis of Gastric Cancer Transcriptome Allows the Identification of Histotype Specific Molecular Signatures With Prognostic Potential
por: Carino, Adriana, et al.
Publicado: (2021)

The Bile Acid Sensor FXR Is Required for Immune-Regulatory Activities of TLR-9 in Intestinal Inflammation
por: Renga, Barbara, et al.
Publicado: (2013)

Divergent Effectiveness of Multispecies Probiotic Preparations on Intestinal Microbiota Structure Depends on Metabolic Properties
por: Biagioli, Michele, et al.
Publicado: (2019)

The Bile Acid Receptor GPBAR-1 (TGR5) Modulates Integrity of Intestinal Barrier and Immune Response to Experimental Colitis
por: Cipriani, Sabrina, et al.
Publicado: (2011)

UDCA, a novel strategy for preventing SARS-CoV-2 infection via FXR-mediated ACE2 downregulation: UDCA and SARS-CoV-2 infection
por: Chen, Mengjiao, et al.
Publicado: (2023)

Impaired Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling
por: Cipriani, Sabrina, et al.
Publicado: (2015)

Correction: The Bile Acid Receptor GPBAR-1 (TGR5) Modulates Integrity of Intestinal Barrier and Immune Response to Experimental Colitis
por: Cipriani, Sabrina, et al.
Publicado: (2013)

Bile Acids Activated Receptors in Inflammatory Bowel Disease
por: Biagioli, Michele, et al.
Publicado: (2021)

FXR and NASH: an avenue for tissue-specific regulation
por: Henry, Zakiyah, et al.
Publicado: (2023)

Differential effects of norUDCA and UDCA in obstructive cholestasis in mice
por: Fickert, Peter, et al.
Publicado: (2013)

Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H(2)S Generation and Endothelin-1
por: Renga, Barbara, et al.
Publicado: (2015)

Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain
por: Carino, Adriana, et al.
Publicado: (2020)

Structure-based drug design targeting the cell membrane receptor GPBAR1: exploiting the bile acid scaffold towards selective agonism
por: Di Leva, Francesco Saverio, et al.
Publicado: (2015)

Glyceric Prodrug of Ursodeoxycholic Acid (UDCA): Novozym 435-Catalyzed Synthesis of UDCA-Monoglyceride
por: Zappaterra, Federico, et al.
Publicado: (2021)

Metabolic Variability of a Multispecies Probiotic Preparation Impacts on the Anti-inflammatory Activity
por: Biagioli, Michele, et al.
Publicado: (2017)

The Bile Acid Sensor FXR Protects against Dyslipidemia and Aortic Plaques Development Induced by the HIV Protease Inhibitor Ritonavir in Mice
por: Mencarelli, Andrea, et al.
Publicado: (2010)

FXR an emerging therapeutic target for the treatment of atherosclerosis
por: Mencarelli, Andrea, et al.
Publicado: (2010)

Modulation of Intestinal Microbiota by the Probiotic VSL#3 Resets Brain Gene Expression and Ameliorates the Age-Related Deficit in LTP
por: Distrutti, Eleonora, et al.
Publicado: (2014)

Dissociation of Intestinal and Hepatic Activities of FXR and LXRα Supports Metabolic Effects of Terminal Ileum Interposition in Rodents
por: Mencarelli, Andrea, et al.
Publicado: (2013)

Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis
por: Cipriani, Sabrina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4oggf1fe22f3dhp1nfa00avuhf